Hematology

TRX103 is also being evaluated for the prevention of graft versus host disease (GvHD) in patients undergoing HLA-mismatched HSCT.

Going forward, the company is mainly focused on distributing the gene therapy in the United States, Germany, and Italy.

Review top news and interview highlights from the week ending August 9, 2024.

Elderly patients were at higher risk of infections and subsequent malignant neoplasms.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.

The open-label, multicenter phase 1/2 STARLIGHT-1 study takes the form of a dose escalation trial with a 3+3 design.

The company has filed a protocol amendment with the EMA and anticipates resuming recruitment imminently.

Review top news and interview highlights from the week ending August 2, 2024.

There were no new cases of CRS past 2 weeks after infusion and non-relapse mortality was driven by infection in follow-up.

The trial will be open to patients with relapsed/refractory large-B-cell lymphoma and chronic lymphocytic leukemia.

The chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

Pending positive outcomes, Actinium plans to later evaluate Iomab-ACT as a conditioning agent for SCD gene therapies.

The European Commission granted conditional marketing authorization under the name Beqvez to the European Union.

Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies, Dana-Farber Cancer Institute, discussed GPRC5D-targeted CAR-T, BMS-986393.

Review top news and interview highlights from the week ending July 26, 2024.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s work on using ultrasound mediated gene delivery to target hemophilia A.

Cell and gene therapies can transform the paradigm of care for patients with chronic, complex conditions, but these therapies come at an up-front cost of several million dollars per treatment, complicating the pipeline of access to them.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison discussed the state of cell and gene therapy development.

Most participants maintained only over a 5% FVIII level after at least 15 months of follow-up.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s preclinical research with UMGD for the treatment of hemophilia.

Both bluebird bio and Vertex Pharmaceuticals have received unfavorable opinions from the Office of the Inspector General on the matter.

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Review top news and interview highlights from the week ending July 19, 2024.

The associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.